167 related articles for article (PubMed ID: 22205960)
21. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
22. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of c-Met inhibitor for advanced prostate cancer.
Tu WH; Zhu C; Clark C; Christensen JG; Sun Z
BMC Cancer; 2010 Oct; 10():556. PubMed ID: 20946682
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
25. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.
Varkaris A; Corn PG; Gaur S; Dayyani F; Logothetis CJ; Gallick GE
Expert Opin Investig Drugs; 2011 Dec; 20(12):1677-84. PubMed ID: 22035268
[TBL] [Abstract][Full Text] [Related]
26. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.
Selth LA; Das R; Townley SL; Coutinho I; Hanson AR; Centenera MM; Stylianou N; Sweeney K; Soekmadji C; Jovanovic L; Nelson CC; Zoubeidi A; Butler LM; Goodall GJ; Hollier BG; Gregory PA; Tilley WD
Oncogene; 2017 Jan; 36(1):24-34. PubMed ID: 27270433
[TBL] [Abstract][Full Text] [Related]
27. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
28. Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
Tong D; Liu Q; Liu G; Xu J; Lan W; Jiang Y; Xiao H; Zhang D; Jiang J
Cancer Lett; 2017 Mar; 389():23-32. PubMed ID: 28043910
[TBL] [Abstract][Full Text] [Related]
29. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
30. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
32. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
33. MET and VEGF: synergistic targets in castration-resistant prostate cancer.
Aftab DT; McDonald DM
Clin Transl Oncol; 2011 Oct; 13(10):703-9. PubMed ID: 21975330
[TBL] [Abstract][Full Text] [Related]
34. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.
Ettinger SL; Sobel R; Whitmore TG; Akbari M; Bradley DR; Gleave ME; Nelson CC
Cancer Res; 2004 Mar; 64(6):2212-21. PubMed ID: 15026365
[TBL] [Abstract][Full Text] [Related]
35. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
[TBL] [Abstract][Full Text] [Related]
36. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
37. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
Gupta A; Cao W; Chellaiah MA
Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
[TBL] [Abstract][Full Text] [Related]
38. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Jing C; Ning J; Yuanjie N
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2137-43. PubMed ID: 22868821
[TBL] [Abstract][Full Text] [Related]
39. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
40. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
